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Combination of methotrexate and sulphasalazine in patients 
with rheumatoid arthritis: pharmacokinetic analysis and 
relationship to clinical response
i
CEES J. HAAGSMA1, FRANS G. M. RUSSEL2, TOM B. VREE3, PIET L. C. M. VAN RIEL1 & LEVINUS B. A. 
VAN DE PUTTE1
departm ent of Rheumatology, 2Department of Pharmacology and ^Department of Clinical Pharmacy, Academic 
Hospital Nijmegen and Faculty of Medical Sciences, Catholic University Nijmegen, The Netherlands
1 The influence of sulphasalazine (SASP) on the pharmacokinetics of low dose 
methotrexate (MTX) and the relation between pharmacokinetic variables and 
clinical response was studied in 15 patients with active rheumatoid arthritis 
despite > 6 months of SASP treatment.
2 SASP was stopped for 2 weeks. Thereafter a single oral dose of 7.5 mg MTX 
was administered after a standard breakfast. Blood was sampled initially every 
30 min, thereafter hourly during 8 h. Urine was sampled every hour. Then
*
2000 mg SASP daily +  7.5 mg MTX weekly was given. After 4 weeks the 
same procedure was repeated supplemented with concomitant administration 
of 1000 mg SASP. Clinical measurements included Ritchie articular index, 
number of swollen joints, ESR and the disease activity score. Pharmacokinetic 
analysis was performed using a two-compartment model with first order 
absorption and lag time. Results are given as mean (s.d.). Paired t-test or 
signed rank test were applied in the statistical analysis.
3 Pharmacokinetics of MTX without vs with SASP, means ±  s.d. were as follows:
AUC: 673 + 179 vs 628 + 210 (95% confidence interval [Cl] of the difference 
was -7 1  to 159)ngm l-1 h, MRT: 5.2 + 1.3 vs 5.2 +1.1 (95% Cl -0 .4  to 
0.4) h, t4 : 4.3±1.1 vs 4.2± 1.1 (95% Cl -0 .3  to 0.5) h, V/F: 59.3 ±29.3 vs 
65.5+25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3±5.0 vs 13.5±4.8 (95% Cl -4 .5  
to 2.3) 1 h -1. CLr/F: 6.2±1.3 vs 6.3±2.1 (95% Cl -1 .3  to 1.1) 1 h-1. AU P
values were ^0.3.
4 A weak correlation existed between the change of ESR and the MRT, the
and the V/F (Spearman correlation coefficients of 0.43, 0.50 and 0.50 
respectively, 0.05 < P  <  0.1 ).
5 There is no significant influence of chronic SASP administration on the 
pharmacokinetics of MTX or vice versa. Of the clinical variables, only the 
ESR correlated consistently with some pharmacokinetic variables of MTX.
Keywords sulphasalazine methotrexate combination pharmacokinetics rheu­
matoid arthritis clinical study
Introduction
Rheumatoid arthritis (RA) is a disease which is often 
characterized by progressive and irreversible joint 
destruction, which occurs early in the course of the 
disease as is seen by radiographical analysis [1 ] . The
results of current drug therapy are not at all satisfactory, 
as is shown in various ‘survival’-curves (i.e. analysis of 
the duration of use) of second-line antirheumatic drugs 
[2 ]. To tackle these problems proposals were brought 
forward to leave the current strategy of giving antirheu­
matic drugs in a sequential way, starting with the least
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toxic one [3, 4]. One of these proposals is to combine 
different disease modifying antirheumatic drugs 
(DMARJDs).
Various review articles and editorials have addressed 
the issue of combining DMARDs [5, 6], The general 
impression is that while definite conclusions cannot be 
drawn due to lack of randomized controlled studies, 
there are some clues that combination therapy is more 
effective but also more toxic. Which drugs to combine 
and how to use these combinations, e.g. to employ the 
so called step-down bridge approach [4] or to start 
with one and when a satisfactory response is lacking 
add another [5], is unclear.
The present study focuses on RA patients who are 
resistant to sulphasalazine (SASP) therapy. Methotrex­
ate (MTX) was chosen to be added to SASP because it 
is likely to be superior to some other DMARDs 
with respect to efficacy and toxicity [7, 8]. Also, it 
has a relatively quick onset of action and the side 
effects are generally quite manageable. In the sparse 
literature describing case histories in which this combi­
nation was used, a favourable effect has been described
[9].
SASP consists of two compounds, sulphapyridine and 
mesalazine, linked by an azo-bond, which is split by 
intestinal bacteria. SASP is variably absorbed, with 
estimates ranging from 10 to 30%, and undergoes 
extensive enterohepatic recycling. The metabolites of 
SASP have complex dispositional characteristics [10]. 
MTX is an antifolate drug. There is interindividual 
variation in its bioavailability. It is bound to plasma 
proteins (35-50%) and undergoes mainly renal elimin­
ation (tubular secretion) [11].
There are very few data concerning the toxicity and 
no reliable data addressing the pharmacokinetic inter­
action of this combination. Theoretically there is the 
possibility of a pharmacokinetic interaction at the renal 
level between MTX, SASP, sulphapyridine and other 
metabolites, since these are anionic drugs that could 
compete for the tubular organic anion excretory mechan­
ism [12, 13]. The interaction of sulphamethoxazole- 
trimethoprim with MTX leading to increased toxicity is 
well known. This interaction could be due to interference 
with folate dependent metabolism, although for sulpho- 
namides as sulphasalazine such an effect has only been 
described in vitro [14], not in vivo. The possibility of a 
pharmacokinetic explanation of this increased toxicity 
has been explored [15, 16], but not concerning other 
sulphonamides like SASP and its metabolites, with low- 
dose MTX.
Few data also exist relating pharmacokinetic param­
eters or blood levels to the clinical response of MTX or 
SASP, and there are no data on this relationship in 
patients using the combination of the two drugs. When 
there is a pharmacokinetic interaction, e.g. an impeded 
excretion of MTX due to competition for renal tubular 
excretory pathways, it could lead to prolonged exposure 
to the drug, thus explaining possible clinical results of 
the combination.
In the present study we tried to answer the primary 
question of whether there is a pharmacokinetic inter­
action between SASP and MTX, and the secondary
question of whether pharmacokinetic parameters can 
predict response and/or toxicity in RA patients treated 
with the combination of SASP and MTX.
Methods
Patients
As part of a larger open randomized clinical trial (40 
patients) comparing MTX and the combination of MTX 
and SASP, the first consecutive 15 patients with RA 
(ACR criteria 1987) randomized to the combination 
were included in the study. All were receiving SASP 
before inclusion in the study for at least 6 months, but 
did not experience sufficient efficacy of the drug. All had 
to have an estimated creatinine clearance (Cockcroft’s 
rule) >75 ml min“ 1, normal haematological and liver 
enzyme values. All patients had NSAIDs as co­
medication, in a dose which was kept strictly the same 
throughout the study, as was all other co-medica­
tion. Ethics Committee approval was obtained from the 
Commissie Experimenteel Onderzoek op Mensen, 
Academic Hospital Nijmegen, the Netherlands. All 
patients gave their written informed consent.
Experimental design
After taking a serum sample for measurement of trough 
levels (15 h after the last dose of SASP) of SASP, 
sulphapyridine and acetylated sulphapyridine, the medi­
cation was discontinued for 2 weeks. NSAIDs were 
continued in a stable dose throughout the study, and 
other co-medication was kept the same throughout the 
period of the study. Two weeks later the pharmacokinetic 
investigation was performed: patients received three 
tablets of 2.5 mg MTX (Emtrexate®, Pharmachemie, 
Haarlem, The Netherlands) given in a single dose, after 
a standardized breakfast. Blood was collected every 
30 min for the first 2 h and hourly for a total of 8 h 
thereafter. Urine was collected hourly.
Subsequently patients were given 7.5 mg of MTX 
weekly in a single dose on the same day of the week 
combined with SASP tablets 500 mg (Salazopyrine EC®, 
Pharmacia, Uppsala, Sweden) two tablets twice daily.
After 4 weeks the same pharmacokinetic investigation 
was repeated; additionally a sample for determination 
of SASP and metabolites was taken before ingestion of 
the tablets, and the patients received two tablets 
of 500 mg of Salazopyrine EC® together with the MTX 
in a single dose.
The concentration of MTX in plasma was determined 
using the TDX-immunoassay [17] (lower detection 
limit 4.5 ng ml-1, interday CV 1.4%, intraday CV 0.4%). 
In urine the MTX concentration was determined using 
h.p.l.c. analysis (lower detection limit 0.25 |ig ml“ 1, 
interday CV 4.8%, intraday CV 1.4%) [18]. SASP and 
metabolite concentrations were measured by h.p.l.c. 
(lower detection limit 1 |ig ml-1, interday CV 1.3—3.4%, 
intraday CV 1.0-3.2%) [19].
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The MTX drug levels were analysed using both content (mmol l " 1) and haematocrit, mean red cell 
model-dependent and model-independent methods. volume (ft), WBC count with differential count, platelet 
Curve fitting was done by using the nonlinear regression count, alanine and aspartate aminotransferase, gamma
glutamyl transferase, alkaline phosphatase and creatin­
ine in serum (nmol I-1).
Toxicity was monitored every 4 weeks by interviewing
[201
(1/C)
amounts excreted weighted equally. Plasma concen­
tration-time curves were analyzed according to a linear the patient, physical examination and laboratory investi-
open two compartment model with first order abs< 
tion, using the following equation:
C(i)=A1*e expHi-^gVxj) + A2-e exp(-(f-ilftg)/x2)
(Ai + A2)• e exp(-(i-ilag)/xabs)
where:
A * :
gâtions. The following laboratory values were considered 
as an adverse drug reaction: a WBC count of less than 
3.5* 109 1“ 1, platelets less than 120* 109 I“ 1, a decrease 
of haemoglobin content of >1.0 mmol I” 1, an increase 
of serum creatinine of >25%  and an increase of liver 




intercept of the i-th exponential phase on the 
Y-axis (ng ml“ 1)
time constant of the i-th exponential phase (h) 
absorption time constant (h) 
absorption lag time (h)
Statistical analysis
To compare the values of the derived pharmacokinetic 
parameters and blood levels during single drug use and
The cumulative amount of drug excreted in the urine during the use of the combination, paired f-tests were
unchanged vs time was calculated as follows:





cumulative amount of drug excreted unchanged 
in urine to time infinity (mg) 
excretion time constant (h) 
excretion lag time (h)
used in the case of normally distributed values and 
signed rank tests were employed when data had a 
skewed distribution. 95% confidence intervals were 
calculated using 2.145-s.e.mean,
The goodness of fit to the plasma concentration and 
cumulative excretion data were evaluated through the 
deviations between observations and model-predicted
From these equations the following pharmacokinetic




A r O C i - T a J  +  A a - C c 2 ^ a b s ) )
A r ( T , 2 - T abs2) +  A 2 *(T22 ^ a b s  )
t
AUMC/AUC
l n 2  • X2
CL/F  
V/F 
CL k/F  
where:
Df AUC
D • AUMC/( AUC)2 -  D • xabs/AUC 
( A0°°/D) • CL ¡F
values expressed as: rl = 1 — 2(Dev) /E(Obs) .
To test the association between the derived pharmaco­
kinetic parameters during the use of the combination 
and clinical variables (the change from week 0 to week 
24 concerning the Ritchie articular index, the number 
of swollen joints, the ESR, the DAS score, and the 
occurrence of toxicity), Spearman rank correlation 
coefficients were tested.
AUC: area under the curve from O-+00, AUMC: area Results 
under the first moment curve from O-+00, MRT: mean
residence time, tiX : elimination half life, CL: total body Fifteen RA patients were included in
clearance, F: fraction absorbed (unknown), V: volume 
of distribution, CLR: renal clearance.
AUC and AUMC were also calculated model- 
independently by application of the linear trapezoidal months (s.d. 12.2). I 
rule (from f = 0 to 8h  and by extrapolation of the levels of MTX (with and without SASP) and
. The 
female/malemean age was 59.5 years (s.d. 11.7), 
ratio was 12/3, the mean duration of the illness was 4.8 
years (s.d. 4.1), the mean duration of SASP-use was 18.7
9
« 4 1 the mean r:l ti
* •
2
terminal phase of the plot to infinity). the mean cumulative urinary excretion of MTX. Table 1
shows the model-dependent vs of the derived
parameters of MTX pharmacokinetics. Model-
Clinical evaluation independent analysis revealed virtually the same values 
(data not shown). The goodness of fit expressed as the 
Patients were evaluated 2 weeks before entry, and at mean coefficient of determination was 0.97 (s.d. 0.07),
weeks 0, 4, 8, 12, 16, 20 and 24. All clinical evaluations range 0.66-0.99, very acceptable fits. The
were performed by one observer (CJH). pharmacokinetics of MTX with or without MTX were
The following changes comparing week 0 and week very similar (Table 1). The steady state trough levels of
24 were evaluated: the DAS (disease activity score [21]), SASP and metabolites were not by
the number of painful joints (53 joints were evaluated), co-administration of MTX either (Table 2). The clinical
the Ritchie Articular Index, the number of swollen joints results of 24 weeks of treatment are shown in Table 3.
(maximum of 48 joints) and general wellbeing expressed Six patients experienced some form of toxicity. There
by the patient on a visual analogue scale of 0-100 mm. were no consistent correlations between the derived
Compliance was checked by interviewing the patient. pharmacokinetic parameters and the results of treatment
Laboratory evaluation consisted of ESR, haemoglobin or toxicity except for the decline in ESR which correlated
© 1996 Blackwell Science Ltd British Journal o f  Clinical Pharmacology 42, 195-200
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Figure 1 Plasma concentration-time curves of methotrexate
without ( • )  and with sulphasalazine (O). Values are 
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Figure 2 Cumulative urinary excretion of methotrexate
without ( • )  and with sulphasalazine (O). Values are 
presented as mean and s.d.
with MRT, titZ and volume of distribution (Spearman 
rank correlation coefficients 0.44, 0.51 and 0.50, P values 
0.05, 0.05 and 0.1, respectively).
Discussion
This study shows that there is no pharmacokinetic 
interaction between SASP and MTX in doses used to
treat rheumatoid arthritis. Nor was there a consistent 
correlation between pharmacokinetic parameters of 
MTX and measures of efficacy and toxicity.
In the 15 RA patients studied, the mean values of the 
key parameters of single (low) dose MTX pharmaco­
kinetics, e.g. the area under the curve (AUC), the mean 
residence time (MRT) and the total body clearance 
were statistically not different, without and with con­
comitant chronic administration of SASP. Also, the 
trough serum levels of SASP and major metabolites 
were comparable with or without MTX. A type II error 
seems unlikely given the relatively narrow 95% confi­
dence intervals of the individual differences between the 
pharmacokinetic variables of the drugs administered 
singly and in combination. The disease activity of the 
patients variably decreased and there was considerable 
interindividual variation in the pharmacokinetics of the 
single dose MTX, but there was no consistent correlation 
between the two. A weak correlation existed between 
ESR and the pharmacokinetic parameters MRT, tiiZ 
and V/F  (0.05 < P  <0.1). We chose to study the kinetics 
of MTX in detail and of SASP only by trough levels for 
the following reasons. First, given the large difference 
between the dose of MTX and SASP, the latter is 
possibly more likely to influence the pharmacokinetics 
of the first than vice versa. Second, because we wanted 
to study the steady state of SASP, trough levels reflect 
well enough the levels of SASP and its major metabolites 
to which the body is exposed. The improved clinical 
response to the combination of MTX and SASP, 
previously reported in a clinical trial [22], cannot 
therefore be explained by altered pharmacokinetics of 
MTX or SASP and its major metabolites.
The values of the pharmacokinetic parameters of 
MTX found in our study are in line with those found 
by others [23, 24]. This is the first study specifically 
dealing with the possible pharmacokinetic interaction 
between SASP and MTX. Although one other study 
[25] mentioned this combination in children with 
juvenile rheumatoid arthritis, no reliable data concerning 
the pharmacokinetic interaction between the two com­
pounds are extractable from that article.
We measured MTX levels in blood and urine for 8 h. 
There was an excellent fit of the model to the data. The 
comparability of model-dependent and model indepen­
dent results was good. We believe it is unlikely that 
longer sampling times would have led to other 
conclusions.
The dose of NSAIDs and other concommittant 
medication was kept strictly the same, avoiding a 
possible bias in the results. Although some studies have 




of the concommittant administration of NSAIDs on the 
results is therefore unlikely.
There are various abstracts describing the relationship 
between the pharmacokinetics of MTX and clinical 
results of the drug in rheumatoid arthritis. Furst [29] 
found that toxicity correlated with 1 h levels of MTX.
[30] the elimination
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Table 1 The pharmacokinetics of MTX without and with concurrent administration of sulphasalazine
MTX








CL/ ¥ { l  h~{) CLr/F (/ / r 1 )
12.3 (5.0) 6.2 (1.3)
MTX + SASP 628 (210) 5.2 (1.1) 4.2 (1.1) 65.5 (25.3) 13.4(4.8) 6.3 (2.1)
Difference
(95% Cl)
44 (-71,159) 0.0 (—0.4,0.4) 0.1 (-0.3,0.5) 6 .2 (-23.8,11.4) 1.1 (-4.5,2.3) 0.1 (— 1.3,1.1 )
P value 0.4 0.5 0.6 0.3
■ M I l W
0.4
¡ ¡ i l s w w s a t y j J X
AUC = area under curve, MRT = mean residence time, titZ» half life of elimination, V «  volume of distribution. F »  
absorbed (unknown), CL = total body clearance, CLR=* renal clearance. Values are presented as means (s.d,) unless otherwise st
Table 2 Trough-levels* of sulphasalazine (SASP) and major metabolites 
during SASP only and after 4 weeks of combination treatment with SASP and 
methotrexate (MTX)
Sulphapyridine ac-SSulphapyridine
SASP (¡.ig ml l ) (fig ml ~1) ( f.ig ml ~1 )
SASP only 3.3(2.1-8.2) 10.4(6.3-21.4) 10.5(7.0-16.8)
SASP + MTX 3.3 (2.8-9.0) 11.2 (7.0--18.9) 12.5 (7.5-18.3)
P value 0.2 0.4 0.7
*Medians (lst-3rd quartile).
Table 3 Clinical results of the 15 patients
Variable Week Q Week 24 P value*
Ritchie articular index 16 (12-26) 3(2-7) 0.0001
Number of painful joints 26 ( 17-32) 4(2-10) 0.0001
Number of swollen joints 19 (18-28) 9(2-14) 0.0001
Morning stiffness (min) 120 (30-180) 5(0-90) 0.01
ESR (mm) 40 (30-53) 18 (11-37) 0.007
VAS general health (mm) 64(36-81) 24(19-45) 0.02
Disease activity score 4.9 (4.7-6.2) 2.9 (1.8-3.8) 0.001
Results are expressed as medians (upper and lower quartiles). *The 
between week 0 and week 24 was tested.
but not the AUC correlated with the number of tender lational analysis, there was no consistent relatio
1 Van der
joints. However, no consistent pattern of correlation between pharmacokinetic 
between pharmacokinetics and efficacy or toxicity of efficacy £
MTX emerges. A study by Lafforgue et a l  [31] failed 
to show any relationship between pharmacokinetics and
efficacy. This is somewhat surprising because a dose- References 
effect relationship is clinically obvious for all who work 
with this agent in rheumatoid arthritis and this was 
demonstrated in a study by Seideman [32]. Although 
our results have to be interpreted carefully because the 
pharmacokinetics of MTX were compared with the 
clinical results of the combination, in our study too no 
consistent correlation emerged. In most studies including 
ours, however, a small number of patients was investi­
gated, and given the large interindividual variation a 
type II error (assuming no correlation when in fact 
there may be one) possibly conceals important
relationships.
In conclusion, no pharmacokinetic interaction 
between low-dose MTX and SASP could be demon­
strated in patients with rheumatoid arthritis. Although 
the sample size was relatively small for definite corre-
of
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